礼来将以每股14美元的价格收购自身免疫药物开发商Ventyx Biosciences，交易价值达12亿美元。Ventyx正在开发多种治疗药物，包括治疗克罗恩病和溃疡性结肠炎等炎症性肠病的口服疗法，以及治疗免疫相关疾病、心脏代谢疾病和神经退行性疾病的药物。此外，该公司正在进行中期试验的一种药物针对的是与肥胖有关的心血管疾病，有可能与礼来公司的代谢和免疫专营权形成互补。该交易预计将于今年上半年完成。
礼来将以每股14美元的价格收购自身免疫药物开发商Ventyx Biosciences，交易价值达12亿美元。Ventyx正在开发多种治疗药物，包括治疗克罗恩病和溃疡性结肠炎等炎症性肠病的口服疗法，以及治疗免疫相关疾病、心脏代谢疾病和神经退行性疾病的药物。此外，该公司正在进行中期试验的一种药物针对的是与肥胖有关的心血管疾病，有可能与礼来公司的代谢和免疫专营权形成互补。该交易预计将于今年上半年完成。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.